Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2007

View Archived Issues

Aripiprazole improves psychotic symptoms in Alzheimer's dementia patients

Gabapentin ineffective in tinnitus studies

Pramipexole to be evaluated for Tourette's syndrome / News in Context

BioAlliance updates clinical development for Loramyc and acyclovir Lauriad

DOR BioPharma enters named patient access program with Orphan Australia for orBec

Cytos initiates two phase II studies of Immunodrug CYT003-QbG10 in allergy indications

Oasmia enters license and distribution agreement with Orion for Paclical

In vitro results suggest potential benefit of ICA-27243 as an anticonvulsant

New therapeutic agents for metabolic disorders imparted in recent patents

Recent patents describe novel psychopharmacological agents

Novel therapeutic agents for cardiovascular disorders reported in recent patent literature

Symptomatic and asymptomatic QTc prolongation observed in phase I trial of ARQ-171

FDA grants AstraZeneca six months pediatric exclusivity patent extension for Arimidex

GSK stands by Serevent and Advair following meeting with FDA

Amarin initiates phase I clinical trial of treatment for niacin-induced flushing

Sucampo Pharma initiates phase IIb study of lubiprostone in Japan

European Commission grants orphan medicinal product designation to Revlimid

First patient completes StemCells' phase I clinical trial of HuCNS-SC

Sanofi-aventis and Astellas restructure Japanese joint venture Fujisawa sanofi-aventis

Bavarian Nordic reports positive results from phase II trial of Imvamune smallpox vaccine

Forest Laboratories reports positive results from phase III study of Lexapro

Lundbeck reports third quarter 2007 results

A potential role for CLCN2 in absence epilepsy

GABA-A alpha1 subunit misfolding caused by mutations associated with juvenile myoclonic epilepsy

Pediatric hypertension indication for Novartis' Diovan receives FDA approval

Health Canada approves Merck Frosst's Isentress for HIV-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...